Dr. Bauml Discusses Liquid Biopsies in Lung Cancer

Video

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Liquid biopsies are used by clinicians to look for a wide variety of resistance mutations when giving a targeted therapy. According to Bauml, as we expand liquid biopsies, it is going to be possible to assess tumor mutational burden, leading to better decisions regarding immunotherapy, explains Bauml.

A retrospective analysis of a randomized study determined that a liquid biopsy that measures tumor mutational burden showed promise as an aid for predicting benefit in patients with lung cancer treated with a checkpoint inhibitor. Tumor mutation burden in blood ≥16 had a significant association with improved progression-free survival in patients treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

There was an additional study that looked at patients who had a resection of their lung cancer, and liquid biopsies were used to follow those patients to determine when the relapse would occur. The other role for liquid biopsies is to monitor those patients to watch the genetic landscape.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,